OKYO Pharma (OKYO) Stock Overview
A clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
OKYO Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
OKYO Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.75 |
| 52 Week High | US$3.35 |
| 52 Week Low | US$1.03 |
| Beta | -0.23 |
| 1 Month Change | -38.16% |
| 3 Month Change | -22.01% |
| 1 Year Change | 59.82% |
| 3 Year Change | -67.76% |
| 5 Year Change | -81.07% |
| Change since IPO | -84.48% |
Recent News & Updates
Shareholder Returns
| OKYO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.9% | -1.2% | -1.4% |
| 1Y | 59.8% | 27.8% | 10.9% |
Return vs Industry: OKYO exceeded the US Biotechs industry which returned 25.7% over the past year.
Return vs Market: OKYO exceeded the US Market which returned 10.7% over the past year.
Price Volatility
| OKYO volatility | |
|---|---|
| OKYO Average Weekly Movement | 15.8% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: OKYO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: OKYO's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 4 | Bob Dempsey | okyopharma.com |
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain.
OKYO Pharma Limited Fundamentals Summary
| OKYO fundamental statistics | |
|---|---|
| Market cap | US$111.47m |
| Earnings (TTM) | -US$4.61m |
| Revenue (TTM) | n/a |
Is OKYO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OKYO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$6.26m |
| Gross Profit | -US$6.26m |
| Other Expenses | -US$1.65m |
| Earnings | -US$4.61m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.09 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -5.4% |
How did OKYO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/13 01:08 |
| End of Day Share Price | 2026/02/13 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
OKYO Pharma Limited is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| William Wood | B. Riley Securities, Inc. |
| Yi Chen | H.C. Wainwright & Co. |
| Elemer Piros | Lucid Capital Markets |